Skip to main content
Top
Published in: Lung 5/2016

01-10-2016

Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease

Authors: Cheilonda Johnson, Iago Pinal-Fernandez, Radhika Parikh, Julie Paik, Jemima Albayda, Andrew L. Mammen, Lisa Christopher-Stine, Sonye Danoff

Published in: Lung | Issue 5/2016

Login to get access

Abstract

Purpose

Among patients with autoimmune myositis, associated interstitial lung disease (MA-ILD) is a known contributor of excess morbidity and mortality. Recent data on survival in idiopathic inflammatory myopathies originate primarily in Asia and Europe and vary widely. We sought to examine mortality in a large U.S. myositis cohort focusing in particular on the impact of associated ILD.

Methods

A cross-sectional analysis of participants from the Johns Hopkins Myositis Center with autoimmune myositis (polymyositis [PM], dermatomyositis [DM], or clinically amyopathic dermatomyositis [CADM]) was conducted. The primary outcome assessed was all-cause mortality. Cumulative mortality rates were estimated using the Kaplan–Meier test; the Cox proportional hazards model was used to compare group differences in survival.

Results

Eight hundred and thirty-one participants were included with a median follow-up time of 4.5 years. Four hundred thirty-eight (53 %) had PM, 362 (43 %) had DM, and 31 (4 %) had CADM. Ninety-four (11 %) participants had clinically evident ILD. Overall, 51 participants died (6 %). In those without ILD, the survival rates at 1, 5, and 10 years were 99, 95, and 90 %, respectively. In those with ILD, the survival rates at 1, 5, and 10 years were 97, 91, and 81 %, respectively. The risk of death was statistically significantly higher among participants with ILD compared to those without ILD (HR 2.13. 95 % CI 1.06–4.25; p = 0.03).

Conclusions

We analyzed one of the largest known cohorts of patients with autoimmune myositis and found significantly higher mortality rates among those with clinically evident ILD compared to those without clinically evident ILD. Our results suggest that ILD remains an important and significant source of mortality in patients with inflammatory myopathies and as such should be screened for and treated aggressively.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46(4):626–636CrossRefPubMed Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46(4):626–636CrossRefPubMed
2.
go back to reference American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus (2002) Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165(2):277–304CrossRef American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus (2002) Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165(2):277–304CrossRef
3.
go back to reference Fathi M et al (2004) Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 63(3):297–301CrossRefPubMedPubMedCentral Fathi M et al (2004) Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 63(3):297–301CrossRefPubMedPubMedCentral
4.
go back to reference Fathi M, Lundberg IE, Tornling G (2007) Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med 28(4):451–458CrossRefPubMed Fathi M, Lundberg IE, Tornling G (2007) Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med 28(4):451–458CrossRefPubMed
5.
go back to reference Labirua A, Lundberg IE (2010) Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 22(6):633–638CrossRefPubMed Labirua A, Lundberg IE (2010) Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 22(6):633–638CrossRefPubMed
6.
go back to reference Mimori, T., R. Nakashima, and Y. Hosono, Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment. Curr Rheumatol Rep, 2012 Mimori, T., R. Nakashima, and Y. Hosono, Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment. Curr Rheumatol Rep, 2012
8.
go back to reference Torres C et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205–215CrossRefPubMed Torres C et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205–215CrossRefPubMed
9.
go back to reference Danko K et al (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83(1):35–42CrossRef Danko K et al (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83(1):35–42CrossRef
10.
go back to reference Kalluri M, Oddis CV (2010) Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 31(3):501–512CrossRefPubMed Kalluri M, Oddis CV (2010) Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 31(3):501–512CrossRefPubMed
11.
go back to reference Marie I et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622CrossRefPubMed Marie I et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622CrossRefPubMed
12.
go back to reference Takada K, Nagasaka K, Miyasaka N (2005) Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38(5):383–392CrossRefPubMed Takada K, Nagasaka K, Miyasaka N (2005) Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38(5):383–392CrossRefPubMed
13.
go back to reference Moghadam-Kia S, et al (2015) Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 68(5):689–694CrossRef Moghadam-Kia S, et al (2015) Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 68(5):689–694CrossRef
14.
go back to reference Woo JH et al (2013) Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease. Mod Rheumatol 23(3):503–508CrossRefPubMed Woo JH et al (2013) Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease. Mod Rheumatol 23(3):503–508CrossRefPubMed
15.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407CrossRefPubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407CrossRefPubMed
16.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347CrossRefPubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347CrossRefPubMed
17.
go back to reference Macintyre N et al (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26(4):720–735CrossRefPubMed Macintyre N et al (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26(4):720–735CrossRefPubMed
18.
go back to reference Miller MR et al (2005) General considerations for lung function testing. Eur Respir J 26(1):153–161CrossRefPubMed Miller MR et al (2005) General considerations for lung function testing. Eur Respir J 26(1):153–161CrossRefPubMed
19.
go back to reference Grau JM et al (1996) Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 23(11):1921–1926PubMed Grau JM et al (1996) Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 23(11):1921–1926PubMed
20.
go back to reference Douglas WW et al (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164(7):1182–1185CrossRefPubMed Douglas WW et al (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164(7):1182–1185CrossRefPubMed
21.
go back to reference Kang EH et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 44(10):1282–1286CrossRef Kang EH et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 44(10):1282–1286CrossRef
22.
go back to reference Marie I et al (2001) Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 28(10):2230–2237PubMed Marie I et al (2001) Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 28(10):2230–2237PubMed
23.
go back to reference Johnson C et al (2014) Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med 108(10):1542–1548CrossRefPubMed Johnson C et al (2014) Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med 108(10):1542–1548CrossRefPubMed
25.
go back to reference Danieli MG et al (2014) Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev 13(10):1048–1054CrossRefPubMed Danieli MG et al (2014) Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev 13(10):1048–1054CrossRefPubMed
Metadata
Title
Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease
Authors
Cheilonda Johnson
Iago Pinal-Fernandez
Radhika Parikh
Julie Paik
Jemima Albayda
Andrew L. Mammen
Lisa Christopher-Stine
Sonye Danoff
Publication date
01-10-2016
Publisher
Springer US
Published in
Lung / Issue 5/2016
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9896-x

Other articles of this Issue 5/2016

Lung 5/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.